| Literature DB >> 27560699 |
Haoming Wu1, Abinash Padhi2, Junqiang Xu3, Xiaoyan Gong4, Po Tien1,5.
Abstract
The non-pathogenic Human Pegivirus (HPgV, formerly GBV-C/HGV), the most prevalent RNA virus worldwide, is known to be associated with reduced morbidity and mortality in HIV-infected individuals. Although previous studies documented its ubiquity and important role in HIV-infected individuals, little is known about the underlying genetic mechanisms that maintain high genetic diversity of HPgV within the HIV-infected individuals. To assess the within-host genetic diversity of HPgV and forces that maintain such diversity within the co-infected hosts, we performed phylogenetic analyses taking into account 229 HPgV partial E1-E2 clonal sequences representing 15 male and 8 female co-infected HIV patients from Hubei province of central China. Our results revealed the presence of eleven strongly supported clades. While nine clades belonged to genotype 3, two clades belonged to genotype 2. Additionally, four clades that belonged to genotype 3 exhibited inter-clade recombination events. The presence of clonal sequences representing multiple clades within the HIV-infected individual provided the evidence of co-circulation of HPgV strains across the region. Of the 23 patients, six patients (i.e., five males and one female) were detected to have HPgV recombinant sequences. Our results also revealed that while male patients shared the viral strains with other patients, viral strains from the female patients had restricted dispersal. Taken together, the present study revealed that multiple infections with divergent HPgV viral strains may have caused within-host genetic recombination, predominantly in male patients, and therefore, could be the major driver in shaping genetic diversity of HPgV.Entities:
Mesh:
Year: 2016 PMID: 27560699 PMCID: PMC4999292 DOI: 10.1371/journal.pone.0161880
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Number of patients, patient ID, transmission route, CD4 count, HIV viral load, number of clones, and Phi test for each patient analyzed in this study.
| Patient ID | Infection Route | Therapy | CD4 | Viral Load | Viral sequences | PHI Test | |
|---|---|---|---|---|---|---|---|
| Total | Recombinants | ||||||
| JYM_1 | heterosexual | No | 670 | <LDL | 10 | 0 | 0.07865 |
| CBM_2 | heterosexual | HAART | 221 | <LDL | 10 | 0 | NI |
| QCF_3 | paid blood donor | HAART | 405 | <LDL | 10 | 0 | 0.3697 |
| JZM_7 | paid blood donor | No | 429 | UN | 10 | 0 | 1.0 |
| CBM_8 | homosexual | No | 594 | UN | 10 | 0 | 0.03394 |
| QCM_9 | heterosexual | No | 16 | 13900 | 10 | 0 | 1.0 |
| XAM_10 | heterosexual | HAART | 255 | <LDL | 10 | 0 | 1.0 |
| JZM_23 | heterosexual | No | 695 | UN | 10 | 0 | 1.0 |
| CBF_33 | intravenous drug | No | 49 | 178 | 10 | 0 | 1.0 |
| QCF_34 | paid blood donor | HAART | 411 | <LDL | 10 | 0 | NI |
| QCF_35 | heterosexual | HAART | 193 | <LDL | 10 | 0 | 0.1103 |
| CYM_36 | heterosexual | No | 369 | UN | 9 | 0 | 1.0 |
| CYF_38 | heterosexual | HAART | 366 | <LDL | 10 | 0 | 1.0 |
| CYF_41 | heterosexual | HAART | 318 | <LDL | 10 | 0 | 1.0 |
| JZM_46 | homosexual | HAART | 345 | <LDL | 10 | 0 | NI |
| TCF_55 | heterosexual | HAART | 296 | <LDL | 10 | 0 | 0.4319 |
| JZM_58 | heterosexual | HAART | 407 | <LDL | 10 | 0 | 0.007965 |
aThe nomenclature of patients. The first two letters represent sampling locations; the last letter represents the gender of each patient: M for male and F for female; the numeric represent patients' code.
bHIV viral load (RNA copies/ml); UN: undection;
cThere are too few informative characters to use the Phi Test as implemented here.
Patients with recombinant sequences are in bold.
Fig 1Phylogenetic networks of HPgV E1-E2 segments.
(A) A split network, including all sequences, was first constructed. The sequences clustered in eleven clades designated 1 to 11. The outliers are classified as putative intra-subtype recombinants (in red) or a novel clade (in black). (B) Sequences inferring conflicting phylogenetic signals were excluded (recombinant candidates) were removed, and a new split network was constructed.
Fig 2Maximum likelihood tree depicting two and nine clades belong to genotype 2 and genotype 3, respectively.
Nodes with bootstrap values > 70 are mentioned at the base of the nodes. Recombinant sequences were excluded from the analyses. Clades that were recovered in the present study are shown in different colors. GenBank reference sequences representing genotypes 1 to 5 are included in the analyses.
Summary of unique recombination events identified by RDP4 program.
| Patient ID | Recombination Event Number | Breakpoint Positions | Recombinant Sequences | Minor Parental Sequence(s) | Major Parental Sequence(s) | Detection Methods | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| RDP | GENECONV | Maxchi | Chimaera | SiSscan | 3Seq | ||||||
| XAM_27 | 1 | 468–720 | XAM27_4 | XAM27_2/3/5/9(clade 8) | XAM27_7/8(clade 5) | - | 9.39E-10 | 7.52E-10 | 4.46E-10 | 8.22E-10 | 7.74E-21 |
| 2 | 242–742 | XAM27_1 | XAM27_7/8(clade 5) | XAM27_2/3/5/9(clade 8) | - | 3.00E-04 | 2.33E-09 | 2.33E-09 | 1.03E-12 | 1.53E-16 | |
| 3 | 342–516 | XAM27_10 | XAM27_7/8(clade 5) | XAM27_2/3/5/9(clade 8) | - | 1.25E-02 | 2.11E-02 | - | - | 1.32E-07 | |
| 4 | 742–884 | XAM27_6 | XAM27_2/3/5/9(clade 8) | XAM27_7/8(clade 5) | - | 9.20E-04 | 2.67E-02 | - | - | 5.72E-05 | |
| JZM_39 | 1 | 592–701 | JZM39_3 | JZM39_5 | JZM39_1/2/6/7/9(clade 8) | 6.24E-05 | 1.15E-05 | 5.84E-09 | 1.94E-08 | 1.30E-09 | 4.82E-10 |
| 2 | 358–742 | JZM39_3/10 | JZM39_8(clade 2) | JZM39_1/2/6/7/9(clade 8) | - | 6.81E-05 | 1.73E-10 | 7.97E-09 | 8.01E-14 | 1.68E-16 | |
| 3 | 376–814 | JZM39_4 | JZM39_5 | JZM39_1/2/6/7/9(clade 8) | - | 2.79E-05 | 1.62E-05 | 1.53E-05 | 8.29E-07 | 8.63E-11 | |
| 4 | 1–178 | JZM39_8 | JZM39_1/2/6/7/9(clade 8) | clade 2 | 2.60E-06 | - | 5.04E-07 | 4.34E-04 | 1.45E-19 | 8.76E-12 | |
| QCM_31 | 1 | 430–745 | QCM31_3 | QCM31_4/10(clade 8) | QCM31_6(clade 2) | 1.68E-07 | 2.41E-06 | 9.01E-10 | 1.28E-10 | 6.42E-10 | 1.19E-20 |
| 2 | 516–662 | QCM31_7 | QCM31_6(clade 2) | QCM31_4/10(clade 8) | 8.84E-12 | 4.44E-10 | 5.88E-07 | 4.84E-07 | 5.17E-09 | 1.76E-15 | |
| 3 | 70–309 | QCM31_2/8 | QCM31_4/10(clade 8) | QCM31_6(clade 2) | 2.78E-03 | 8.09E-06 | 8.97E-10 | 5.65E-07 | - | 1.57E-14 | |
| 4 | 69 | QCM31_1/9 | QCM31_6(clade 2) | QCM31_4/10(clade 8) | - | 7.78E-05 | 4.00E-04 | 1.11E-03 | - | 3.12E-11 | |
| 5 | 544–780 | QCM31_11 | QCM31_6(clade 2) | QCM31_4/10(clade 8) | 7.78E-07 | 5.83E-06 | 1.37E-09 | 1.75E-07 | 8.31E-03 | 5.14E-14 | |
| 6 | 508–701 | QCM31_8 | JZM39_5 | QCM31_6(clade 2) | - | 2.62E-03 | 1.41E-05 | 1.30E-05 | 7.82E-07 | 1.36E-08 | |
| TSF_37 | 1 | 72 | TSF37_2 | TSF37_1/4/5/8(clade 2) | TSF37_7(clade 1) | - | 8.89E-05 | - | - | 1.98E-13 | 2.27E-07 |
| 2 | 574–853 | TSF37_3 | TSF37_7(clade 1) | TSF37_1/4/5/8(clade 2) | - | 5.47E-05 | 7.70E-08 | 1.52E-07 | 5.41E-08 | 5.02E-14 | |
| 3 | 3–259 | TSF37_6 | TSF37_1/4/5/8(clade 2) | TSF37_7(clade 1) | - | 1.72E-02 | - | - | - | 4.36E-08 | |
| 4 | 770–865 | TSF37_9 | TSF37_7 (clade 1) | TSF37_4(clade 2) | - | 2.40E-02 | 1.91E-04 | 1.50E-02 | - | 3.97E-10 | |
| 5 | 648–870 | TSF37_2/10 | TSF37_1/4/5/8(clade 2) | TSF37_7(clade 1) | - | 3.57E-08 | 1.47E-04 | 1.47E-04 | - | 1.12E-12 | |
| CYM_40 | 1 | 502–682 | CYM40_8 | clade 2 | CYM40_X(clade 1) | - | 1.49E-05 | 1.80E-05 | 1.80E-05 | - | 1.08E-11 |
| QCM_32 | 1 | 180–363 | QCM32_5 | Unknown | QCM32_X(clade 6) | - | - | 3.27E-02 | - | 6.60E-13 | 1.29E-02 |
* = The actual breakpoint position is undetermined (it was most likely overprinted by a subsequent recombination event).
- = No significant P-value was recorded for this recombination event using this method.
a X = The remaining non-recombination sequences of the patient.
The number of sequences shared by the patients for a given clade after the exclusion of recombinant sequences.
| Patient ID | Genotype 3 | Genotype 2 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | |
| JYM_1 | 8 | 1 | |||||||||
| CBM_2 | 10 | ||||||||||
| JZM_7 | 10 | ||||||||||
| CBM_8 | 10 | ||||||||||
| QCM_9 | 8 | 2 | |||||||||
| XAM_10 | 9 | 1 | |||||||||
| 9 | |||||||||||
| CBF_33 | 10 | ||||||||||
| QCF_34 | 10 | ||||||||||
| QCF_35 | 10 | ||||||||||
| 1 | 4 | ||||||||||
| TCF_55 | 10 | ||||||||||
| CYF_38 | 10 | ||||||||||
| JZM_58 | 2 | 8 | |||||||||
| 5 | 2 | ||||||||||
| 9 | |||||||||||
| CYF_41 | 10 | ||||||||||
| 5 | |||||||||||
| JZM_46 | 1 | 9 | |||||||||
| 1 | 2 | ||||||||||
| CYM_36 | 2 | 7 | |||||||||
| JZM_23 | 10 | ||||||||||
| QCF_3 | 10 | ||||||||||
Patients with recombinant sequences are in bold.
Fig 3Nucleotide diversity of each patient.
The bar plots for each individual (A) and patient-specific group (B) show a relatively higher intra-host nucleotide diversity in patients detected with recombination sequences (black) or/and infected with multiple variants (grey) than other patients (white). Nucleotide diversity was evaluated regardless of recombination.